Skip to content
Catalyst

rosuvastatinPapers

Papers about rosuvastatin

papers
651
26 years, by papers

Newest first

451 to 500 of 651

Every paper here, unless its row says otherwiseReturned by a PubMed search for rosuvastatin

  • Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

    The American journal of cardiology2010PMID 20599004

  • Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.

    Current medical research and opinion2010PMID 20731529

  • Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk".

    Circulation. Cardiovascular quality and outcomes2010PMID 20736443

  • Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.

    Pharmacoepidemiology and drug safety2010PMID 20922707

  • Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.

    European journal of heart failure2010PMID 20952767

  • Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

    Cardiovascular drugs and therapy2010PMID 20953684

  • Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

    Clinical cardiology2010PMID 20960535

  • Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.

    The American journal of cardiology2010PMID 21029819

  • Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.

    Lipids in health and disease2010PMID 21050476

  • Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.

    Minerva cardioangiologica2010PMID 21135803

  • Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients.

    Journal of thrombosis and thrombolysis2009PMID 18636229

  • The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.

    International journal of cardiology2009PMID 18706705

  • ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

    Journal of clinical pharmacology2009PMID 18952910

  • Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

    Atherosclerosis2009PMID 18996523

  • Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.

    Journal of lipid research2009PMID 19043140

  • Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging.

    Circulation journal2009PMID 19057091

  • Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.

    Pharmaceutical research2009PMID 19082693

  • Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.

    Journal of cardiovascular pharmacology and therapeutics2009PMID 19158317

  • Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

    Journal of lipid research2009PMID 19168444

  • Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide.

    European journal of heart failure2009PMID 19168876

  • Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.

    European journal of cardiovascular prevention and rehabilitation2009PMID 19174696

  • Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.

    The American journal of cardiology2009PMID 19195498

  • Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.

    International journal of clinical practice2009PMID 19222610

  • Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.

    Journal of nephrology2009PMID 19229822

  • Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.

    Journal of cardiovascular pharmacology and therapeutics2009PMID 19246334

  • Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.

    Diabetes care2009PMID 19265025

  • Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.

    Southern medical journal2009PMID 19279518

  • Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.

    Journal of the American College of Cardiology2009PMID 19281922

  • Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

    Lancet (London, England)2009PMID 19329177

  • A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

    The New England journal of medicine2009PMID 19329822

  • Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

    The New England journal of medicine2009PMID 19332456

  • Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.

    Arteriosclerosis, thrombosis, and vascular biology2009PMID 19359665

  • Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.

    Metabolism: clinical and experimental2009PMID 19411087

  • The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients.

    American journal of transplantation2009PMID 19459810

  • Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?

    Cardiovascular drugs and therapy2009PMID 19543962

  • Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.

    Journal of internal medicine2009PMID 19549094

  • Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).

    The American journal of cardiology2009PMID 19576317

  • Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.

    European heart journal2009PMID 19717850

  • Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia.

    Journal of atherosclerosis and thrombosis2009PMID 19729865

  • A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.

    European journal of cardiovascular prevention and rehabilitation2009PMID 19745745

  • Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.

    Pharmacoepidemiology and drug safety2009PMID 19780020

  • Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.

    Journal of nephrology2009PMID 19810001

  • Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.

    Internal medicine (Tokyo, Japan)2009PMID 19881236

  • Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure.

    European journal of heart failure2009PMID 19889690

  • Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).

    Journal of the American College of Cardiology2009PMID 19892235

  • Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.

    Circulation2009PMID 19917888

  • Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.

    Metabolic syndrome and related disorders2009PMID 19929597

  • Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.

    Clinical nephrology2009PMID 19954720

  • Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

    Circulation. Cardiovascular quality and outcomes2009PMID 20031900

  • Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study.

    Journal of the American College of Cardiology2009PMID 20082929

The next 50 papers

← Previous 50